



ZTW

10159 US PCT

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Paul D. Golian
Type or print name


Signature

10/3/06
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF
EDWIN CLARK, ET AL.
APPLICATION NO: **10/585,261**
FILED: **07/5/2005**
FOR: **BIOMARKERS AND METHODS FOR DETERMINING SENSITIVITY TO
EPIDERMAL GROWTH FACTOR RECEPTOR MODULATORS**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the date of entry of the national stage. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.


Pursuant to the OG Notice of August 5, 2003 for U.S. national applications filed after June 30, 2003, the requirement for submitting a copy of each cited U.S. patent and each cited U.S. patent application publication is waived, and accordingly copies of the U.S. patent and U.S. patent publications are not submitted. Copies of foreign patent documents and non-patent literature, if cited, are enclosed.

5


The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000



Paul D. Golian
Attorney for Applicant
Reg. No. 42,591
Phone: 609-252-4091
Date: 10/3/06



INFORMATION DISCLOSURE STATEMENT BY APPLICANT(S)

(use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

COMPLETE IF KNOWN

Application Number	10/585,261
Filing Date	01/07/2005
First Named Inventor	EDWIN CLARK
Art Unit	
Examiner Name	
Attorney Docket Number	10159 US PCT

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant



PTO/SB/08B (8/03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Use for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT(S)**

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number	10/585,261
Filing Date	01/07/2005
First Named Inventor	EDWIN CLARK
Art Unit	
Examiner Name	
Attorney Docket Number	10159 US PCT


Sheet 2 of 3

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Check box if English language Translation is attached
	2AA	Alizadeh, A. et al., "Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling", Nature, Vol. 403, pp. 503-511 (2000)	
	2AB	Alon, U. et al., "Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays", Proc. Natl. Acad. Sci., Vol. 96, pp. 6745-6750 (1999)	
	2AC	Bittner, M. et al., "Molecular classification of cutaneous malignant melanoma by gene expression profiling", Nature, Vol. 406, pp. 536-540 (2000)	
	2AD	Blanchard, A. et al., "Sequence to array: Probing the genome's secrets", Nature Biotechnology, Vol. 14, pp 1649 (1996)	
	2AE	Cockett, M. et al., "Applied genomics: integration of the technology within pharmaceutical research and development", Current Opinion in Biotechnology, Vol. 11, pp. 602-609 (2000)	
	2AF	Fry, D. et al., "A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase", Science, Vol. 265, pp. 1093-1095 (1994)	
	2AG	Golub, T. et al., "Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring", Science, Vol. 286, pp. 531-537 (1999)	
	2AH	Khan, J. et al., "Gene Expression Profiling of Alveolar Rhabdomyosarcoma with cDNA Microarrays", Cancer Research, Vol. 58, pp. 5009-13 (1998)	
	2AI	Khan, J. et al., "Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks", Nature Medicine, Vol. 7(6), pp. 673-679 (2001)	
	2AJ	Lockhart, D. et al., "Expression monitoring by hybridization to high-density oligonucleotide arrays", Nature Biotechnology, Vol. 14, pp.1675-80 (1996)	
	2AK	Panek, R. et al., "In Vitro Pharmacological Characterization of PD 166285, a New Nanomolar Potent and Broadly Active Protein Tyrosine Kinase Inhibitor", The J. of Pharmacology and Experimental Therapeutics, Vol. 283(3), pp. 1433-1444 (1997)	
	2AL	Riss, T. et al., "Comparison of MTT, XTT and a novel tetrazolium compound MTS for in vitro proliferation and chemosensitivity assays", Mol. Biol. Cell, Vol. 3 (Suppl.), pp. 184a (1992)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant



INFORMATION DISCLOSURE STATEMENT BY APPLICANT(S)

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number	10/585,261
Filing Date	01/07/2005
First Named Inventor	EDWIN CLARK
Art Unit	
Examiner Name	
Attorney Docket Number	10159 US PCT

Sheet 3 of 3

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article(when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Check box if English language Translation is attached
	3AA	Schena, M. et al., "Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray", Science, Vol. 270, pp. 467-470 (1995)	
	3AB	Shipp, M. et al., "Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning", Nature Medicine, Vol. 8(1), pp. 68-74 (2002)	
	3AC	Sørli, T. et al., "Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications", PNAS, Vol. 98(19), pp. 10869-10874 (2001)	
	3AD	Sonneveld, P., "Multidrug resistance in haematological malignancies", J. of Internal Medicine, Vol. 247, pp. 521-534 (2000)	
	3AE	Van't Veer, L. et al., "Gene expression profiling predicts clinical outcome of breast cancer", Nature, Vol. 415, pp. 530-536 (2002)	
	3AF	Wands, J. et al., "High Affinity Monoclonal Antibodies to Hepatitis B Surface Antigen (HB _s Ag) Produced by Somatic Cell Hybrids", Gastroenterology, Vol. 80, pp. 225-32 (1981)	
	3AG	West, M. et al., "Predicting the clinical status of human breast cancer by using gene expression profiles", PNAS, Vol. 98(20), pp. 11462-11467 (2001)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant